Recent News

• 09.15.2026 - Why Combination Therapy May Be ALS’s Most Credible Breakthrough Path
• 01.22.2025 - NeuroSense featuring the VP Quality and Compliance
• 01.15.2025 - NeuroSense featuring the CRA
• 01.15.2025 - NeuroSense featuring the CRA
• 01.08.2025 - NeuroSense featuring the VP Business Development
• 01.08.2025 - NeuroSense featuring the VP Business Development
• 01.02.2025 - NeuroSense featuring the Office Manager
• 01.02.2025 - NeuroSense featuring the Office Manager
• 12.16.2024 - NeuroSense featuring the VP CMC
• 12.10.2024 - NeuroSense featuring the Head of HR

Recent Filings

• 09.09.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.27.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.13.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.13.2026 - EX-99.1 EX-99.1
• 08.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.06.2026 - EX-99.1 EX-99.1
• 07.31.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.31.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.31.2026 - EX-99.1 EX-99.1
• 07.31.2026 - EFFECT Notice of Effectiveness